Spyryx Biosciences Garners $18,000,000 Series A Financing

  • Feed Type
  • Date
    5/8/2015
  • Company Name
    Spyryx Biosciences
  • Mailing Address
    15 TW Alexander Drive Research Triangle Park, NC 27709 USA
  • Company Description
    Spyryx Biosciences is developing next generation therapeutics for obstructive lung diseases with a particular focus on Cystic Fibrosis and COPD. We are dedicated to making a difference in the lives of patients and their families who bravely face these diseases every day.
  • Website
    http://www.spyryxbio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $18,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    The financial strength this money brings to the Company and the significant expertise each of these funds has in pulmonary drug development ideally positions Spyryx to rapidly advance our CF therapeutic into clinical development and to explore the potential for treating COPD.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy